Beta-Blockers Associated with Weight Gain
Traditional beta-blockers without vasodilating properties—including propranolol, metoprolol, atenolol, timolol, and bisoprolol—are associated with weight gain and should be avoided as first-line therapy in patients with overweight or obesity. 1
Beta-Blockers That Cause Weight Gain
High-Risk Agents (Avoid in Weight-Concerned Patients)
Propranolol causes sustained weight gain of approximately 2.3 kg at one year compared to 1.2 kg with placebo (mean difference 1.2 kg), with this difference persisting through three years of treatment 2
Metoprolol tartrate produces significant mean weight gain of 1.19 kg over 5 months, with even greater gains in obese patients (BMI >30 kg/m²: additional 0.90 kg; BMI >40 kg/m²: additional 1.84 kg compared to carvedilol) 3
Traditional beta-blockers as a class are associated with median weight gain of 1.2 kg (range -0.4 to 3.5 kg) in trials lasting ≥6 months, with most weight gain occurring in the first few months of therapy 4, 5
Bisoprolol lists weight gain as an adverse effect in FDA labeling, though specific quantification is not provided 6
Mechanism of Weight Gain
Beta-blockers decrease metabolic rate by approximately 10%, making obesity management more difficult in overweight hypertensive patients 4
These agents have additional negative effects on energy metabolism beyond metabolic rate reduction 1, 4
Beta-blockers can also cause adverse metabolic effects on lipids and insulin sensitivity, compounding weight concerns 1
Beta-Blockers With Lower Weight Gain Risk
Preferred Agents When Beta-Blockers Are Required
Carvedilol (selective beta-blocker with vasodilating component) shows minimal weight gain of only 0.17 kg over 5 months (not statistically significant, P=0.36), representing a treatment difference of -1.02 kg compared to metoprolol 3
Nebivolol (selective beta-blocker with vasodilating component) has less potential for weight gain and minimally affects lipid and glucose metabolism 1, 7
Clinical Algorithm for Beta-Blocker Selection
First-Line Approach for Hypertension in Weight-Concerned Patients
Avoid beta-blockers entirely as first-line antihypertensive therapy in patients with overweight or obesity 1, 4, 5
Choose weight-neutral alternatives: ACE inhibitors, ARBs, or calcium channel blockers as first-line therapy 1, 8
When Beta-Blockers Are Medically Required
Select carvedilol or nebivolol when beta-blockers are necessary for specific indications such as coronary artery disease, heart failure, or arrhythmias 1, 7
Avoid propranolol, metoprolol, atenolol, timolol, and bisoprolol in patients with weight concerns 1, 3, 2
Important Clinical Caveats
Weight gain with traditional beta-blockers occurs predominantly during the first few months of therapy, with no further significant gain thereafter compared to controls 5
The weight gain effect is consistent across demographic characteristics including sex and age 2
Weight changes with beta-blockers show no significant correlation with changes in HbA1c, insulin resistance (HOMA-IR), or blood pressure, suggesting the mechanism is independent of glycemic control 3
Not all beta-blockers demonstrate survival benefits, and extrapolating benefits across the class is inadvisable—agent selection should be guided by specific trial data for the clinical indication 9